74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
GlaxoSmithKline PLC
Closed
Sector Healthcare
1,432 -1
Overview
Share price change
24h
Min
1412.5
Max
1437
Income | -1.2B -58M |
|---|---|
Sales | 128M 8B |
P/E Sector Avg | 23.186 73.394 |
EPS | 0.232 |
Dividend yield | 4.44 |
Profit margin | -0.724 |
EBITDA | -1.7B 1.2B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +9.22 upside |
Dividend yield Sector Avg | 4.44% 3.09% |
|---|---|
Next Earnings | 30 Apr 2025 |
Next Dividend date | 10 Apr 2025 |
Next Ex Dividend date | 15 May 2025 |
Market Cap | 59B |
|---|---|
Previous open | 1433 |
Previous close | 1432 |
News Sentiment
By Acuity
54%
46%
333 / 393 Healthcare
GlaxoSmithKline PLC Chart
Past performance is not a reliable indicator of future results.
Related News
GlaxoSmithKline PLC Forecast
Price Target
By TipRanks
9.22% upside
12 Months Forecast
Average 1,580.42 GBX 9.22%
High 2,290 GBX
Low 1,415 GBX
Based on 12 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.
Sentiment
By Acuity
333 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.